A comparative study of the prevalence of hyperkalemia with the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers.
OBJECTIVE
Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) are increasingly used in a variety of settings including heart failure, renal failure, arterial hypertension, and diabetic nephropathy. The objective of this study was to investigate the prevalence of hyperkalemia with ACEI and ARB use, in a population of the United States veterans. DESIGN, SETTINGS, MATERIAL, AND MEASUREMENTS: Retrospective observational cohort study of 1163 patients on ACEIs and 1168 patients on ARBs in a single Veterans Affairs Medical Center. Electronic medical records were reviewed over a 12-month period with data collected on various demographic, laboratory, comorbidity, and medication related variables.


RESULTS
Hyperkalemia (>5 mEq/L) was observed in 20.4% of patients on ACEIs and 31.0% on ARBs. Severe hyperkalemia (6 mEq/L or higher), was observed in 0.8% of ACEI and 2.8% of ARB users. In univariate logistic regression analyses, diabetes mellitus; serum glucose, total carbon dioxide content, creatinine, and estimated glomerular filtration rate (GFR) were significantly associated with hyperkalemia. ARB use, when compared to ACEI, was associated with a 42% increase in odds of hyperkalemia (odds ratio [OR] = 1.42; p = 0.001) in a model including adjustment for GFR and a 56% increase in odds of hyperkalemia (OR = 1.56; p < 0.001) in a model including adjustment for serum creatinine.


CONCLUSIONS
Hyperkalemia, associated with the use of ACEIs and ARBs, is usually mild and severe hyperkalemia is rare. Hyperkalemia is more common with ARBs than ACEIs. ARB use, when compared to ACEI use, may significantly and independently be associated with increased odds of hyperkalemia.
Sadjadi
Seyed Ali
SA
Section of Nephrology (111N), Jerry L Pettis Memorial Veterans Medical Center, Loma Linda, CA, USA.
McMillan
James I
JI
Jaipaul
Navin
N
Blakely
Patricia
P
Hline
Su Su
SS
Am J Med. 2002 Feb 1;112(2):110-4
11835948
Kidney Int. 2000 Nov;58(5):2084-92
11044229
N Engl J Med. 2001 Dec 6;345(23):1667-75
11759645
N Engl J Med. 2003 May 15;348(20):2007-18
12748317
N Engl J Med. 1990 May 3;322(18):1290-2
2325722
Congest Heart Fail. 2000 Jul-Aug;6(4):193-196
12147952
N Engl J Med. 2001 May 31;344(22):1651-8
11386263
Semin Nephrol. 2004 May;24(3):218-24
15156527
J Clin Pharmacol. 2002 Jul;42(7):754-61
12092742
Am Heart J. 2000 Apr;139(4):609-17
10740141
Intern Med. 2007;46(12):823-9
17575373
J Renin Angiotensin Aldosterone Syst. 2003 Mar;4(1):43-7
12692753
N Engl J Med. 2004 Aug 5;351(6):543-51
15295047
N Engl J Med. 2003 Apr 3;348(14):1309-21
12668699
N Engl J Med. 2001 Sep 20;345(12):851-60
11565517
N Engl J Med. 1999 Sep 2;341(10):709-17
10471456
Arch Intern Med. 2001 Jan 22;161(2):165-71
11176729
J Am Geriatr Soc. 2003 Jan;51(1):123-6
12534856
Diabetes Care. 2003 May;26(5):1402-7
12716796
Arch Intern Med. 2000 Jun 12;160(11):1605-11
10847253
N Engl J Med. 2003 Nov 13;349(20):1893-906
14610160
QJM. 2005 Mar;98(3):199-203
15728401
Nephron Clin Pract. 2005;99(1):c18-23
15637459
J Card Fail. 2007 Aug;13(6):422-30
17675055
N Engl J Med. 2004 Aug 5;351(6):585-92
15295051
Ann Intern Med. 2003 Jun 3;138(11):917-24
12779302
Clin J Am Soc Nephrol. 2009 Apr;4(4):820-9
19346430
Diabetes Care. 2006 Oct;29(10):2210-7
17003295
Curr Opin Nephrol Hypertens. 2002 Jul;11(4):377-81
12105385
N Engl J Med. 2008 Apr 10;358(15):1547-59
18378520
Am J Kidney Dis. 2006 May;47(5):751-60
16632013
J Gen Intern Med. 2000 Dec;15(12):885-90
11119186